IXT-001

IXT-001 is an investigational inhalation therapy being developed by invoX Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug candidate is delivered via the proprietary Softhaler® platform, a high-performance dry powder inhaler (DPI) technology designed to optimize drug deposition in the lungs. While the specific active pharmaceutical ingredient and its molecular target have not been publicly disclosed, IXT-001 is the lead candidate in invoX's respiratory pipeline, which leverages advanced inhalation technology to improve the delivery and efficacy of treatments for pulmonary conditions. The development of IXT-001 is part of a broader strategy by invoX Pharma to utilize the Softhaler® system for delivering a variety of therapeutic modalities, potentially including small molecules or biological agents.